Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Is Moderna stock a buy after the company announced positive results for its flu shot? Is MRNA stock a buy right now?

Is Moderna Stock A Buy As Its Case For A New Flu Vaccine Finally Pans Out?

BioNTech SE

Novavax

Pfizer

Vaccine stocks delivered multibagger returns earlier in the pandemic. Their performance has suffered in recent times as some investors worry about revenue in a post-pandemic world.

The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?

Dollar General

Mullen Automotive

Uncertainty abounds in the market right now. Whether driven by fears tied to surging inflation, rising interest rates, or geopolitical turmoil, investors have plenty to consider moving forward.

3 Shaky Stocks to Sell in October Before It's Too Late

Doximity

Moderna predicts billions of dollars in revenue -- and from multiple products -- in the not-too-distant future. Doximity has a solid earnings track record and is launching new tools to keep clients coming back.

These 2 Top Stocks Are Screaming Buys Right Now

AstraZeneca

Merck

CRISPR Therapeutics

GlaxoSmithKline

Novartis

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

Nobel for mRNA: Which other biotech stocks might be overlooked?

Illumina

Johnson & Johnson

UnitedHealth Group

Zimmer Biomet Hlds

With the current sector-wide downturn, it's not surprising that several large healthcare stocks are currently undervalued, relative to their intrinsic value, based on their fundamentals, cash flows, and future earnings potential.

3 Undervalued Healthcare Stocks to Watch as Sector Struggles

Moderna just reported positive data from its combined flu/coronavirus vaccine candidate and aims to launch a phase 3 trial. The potential product could appeal to people who already go for flu vaccines -- that's about half of Americans.

Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market?

Moderna is a biotech company with high potential upside, despite the decline in demand for its COVID-19 vaccine. The company's mRNA platform approach has advantages over traditional vaccine manufacturing methods. Moderna has a large drug pipeline and plans to launch 15 new mRNA-based medicines over the next five years.

Investing In Moderna: A Speculative Buy For Long-Term Gains

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

Moderna Therapeutics Inc (NASDAQ:MRNA) has filed a new drug submission for its vaccine aimed at preventing respiratory syncytial virus (RSV) in adults aged 60 and older with Health Canada, according to a report by MarketWatch. According to the report, the regulatory submission is based on positive data from a prespecified interim analysis of its ConquerRSV study, which included 37,000 adults aged 60 and older across 22 countries.

Moderna reportedly files submission for RSV vaccine with Health Canada

mRNA-1345 is an investigational vaccine for the prevention of RSV in adults aged 60 years or older TORONTO, ON / ACCESSWIRE / October 5, 2023 / Moderna Biopharma Canada Corp. today announced the filing of a New Drug Submission (NDS) to Health Canada for mRNA-1345, its investigational vaccine candidate for the prevention of RSV in adults aged 60 years or older. This is the first mRNA vaccine candidate for RSV filed in Canada.

Moderna Files for Health Canada Review of its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Investors have worried about Moderna's post-pandemic earnings since the company relies on its coronavirus vaccine for revenue. Moderna has been progressing toward its goal of becoming a multiproduct company.

Can Moderna Achieve Its Most Ambitious Goal Yet?

Moderna Therapeutics Inc (NASDAQ:MRNA) has revealed promising early-stage trial results for its combined Covid and influenza vaccine. Interim phase I/II data suggests the dual jab matches the efficacy of taking separate shots for each virus.

Moderna double flu and Covid jab returns promising early results

Moderna Inc. announced positive interim results from a Phase 1/2 trial of its combination vaccine against COVID-19 and flu on Wednesday, and said it would start a Phase 3 trial for adults aged 50 and above. The trial sought to evaluate the safety and immunogenicity of mRNA-1083 compared to a standard dose influenza vaccine, Fluarix, in adults 50-64 years of age, and against an enhanced influenza vaccine, Fluzone HD, in adults 65-79 years of age.

Moderna reports positive results for combination flu and COVID vaccine

Moderna on Wednesday said its combination vaccine to protect against both COVID-19 and influenza generated a strong immune response compared to individual shots for the viruses in an early-stage study.

Moderna combo COVID-19/flu vaccine succeeds in early-stage trial

Moderna and other vaccine makers like Pfizer believe combination shots will simplify what people can do to protect themselves against Covid, RSV and the flu.

Moderna combination Covid, flu vaccine moves to final stage trial after positive data

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin Phase 3 trial of mRNA-1083 in adults 50 years and above CAMBRIDGE, MA / ACCESSWIRE / October 4, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim results from the Phase 1/2 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19. Moderna's investigational combination vaccines are designed to deliver value to individuals, providers and healthcare systems through higher compliance, easier administration and greater convenience.

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19

Moderna has announced progress on late-stage programs and forecasts billion-dollar earnings down the road, but the stock continues to stagnate. Investors might be waiting for concrete signs of success before diving in.

Moderna's Shares Could Take Off if These 2 Things Happen

Revenue from Moderna's COVID vaccine will continue for the foreseeable future. Moderna has a deep pipeline with several products in phase 3 trials.

Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID Vaccine

CAMBRIDGE, MA / ACCESSWIRE / September 29, 2023 / Moderna, Inc. (NASDAQ:MRNA) has become aware that TRC Capital Investment Corporation (TRC Capital) has amended its unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price that is now $99.00 per share, down from $107.56 per share under the original offer. TRC Capital's amended offer price of $99.00 per share is lower than the closing price of Moderna common stock on the Nasdaq Global Select Market on September 28, 2023, the last trading day prior to the announcement of the updated offer.

Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation

Amazon

The number of stocks to choose from could feel overwhelming, but you can narrow down the possibilities by focusing on a couple of key elements. It's important to look at future prospects, the strength of product or service offerings, and potential catalysts ahead.

If I Could Only Buy 3 Stocks in 2023, I'd Pick These

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.

Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?

Intuitive Surgical

According to the American Medical Association, U.S. healthcare spending totaled $4.3 trillion in 2021, equal to nearly $13,000 per person. Overall medical expenses account for nearly 20% of U.S. gross domestic product (GDP).

Don't Miss the Boom: 3 Healthcare Stocks Set to Explode Higher

Alaska Air Group

DexCom

Etsy

MGM Resorts

Insulet

ResMed

SolarEdge Technologies

United Continental Hlds

Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as ever.

Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks.

The European Union is in talks with Moderna over a new procurement deal for the company's COVID-19 vaccines amid concerns over a rise in infections in the region, the Financial Times reported on Tuesday.

News for Moderna Stock (MRNA)